Intranasal Oxytocin trial aims to reduce stress in dementia caregivers via fMRI-measured brain changes
Background
Caregivers for individuals with dementia face immense psychological and physical burdens, often leading to chronic stress, burnout, and impaired well-being. Existing support systems may not fully address the profound emotional toll. Oxytocin, a neuropeptide, plays a crucial role in social bonding, empathy, and stress reduction by modulating neural circuits involved in fear and anxiety. Intranasal administration offers a direct route to the brain, making it a promising candidate to alleviate caregiver stress and improve emotional resilience.
Study Design
This randomized, triple-blind, placebo-controlled Phase 2 trial will enroll an estimated 32 caregivers of persons with dementia. Participants will be randomized to receive either Oxytocin Intranasal Spray 12 IU (for those <40 kg) or 24 IU (for those >40 kg), or a placebo. The intervention involves daily intranasal administration (1-2 puffs per nostril) for 21 days. The primary outcome involves assessing changes in brain activity using functional MRI (fMRI) during affective Stroop and Empathy and Theory of Mind (EmpaTom) tasks, measured both pre- and post-treatment.
Results
As this is a currently recruiting Phase 2 clinical trial (NCT06364228), no results or findings are available yet. The study aims to determine if daily intranasal oxytocin administration for 21 days can significantly modulate brain responses related to stress and empathy in dementia caregivers. Researchers hypothesize that oxytocin will lead to measurable changes in neural activity, as detected by fMRI during specific emotional and social cognitive tasks (affective Stroop, EmpaTom). These changes are expected to correlate with improvements in subjective stress levels and overall well-being. The primary objective is to identify neurobiological markers of oxytocin's impact on caregiver burden, potentially revealing dose-dependent effects between the 12 IU and 24 IU regimens. The trial is designed to provide preliminary efficacy data and inform future larger-scale studies on oxytocin as a therapeutic intervention for caregiver support.
Key Findings
- To evaluate if intranasal oxytocin (12 IU or 24 IU daily) reduces stress in dementia caregivers over 21 days.
- To assess changes in brain activity using fMRI during affective Stroop and EmpaTom tasks pre- and post-treatment.
- To compare the effects of 12 IU versus 24 IU oxytocin regimens on neurobiological markers of stress and empathy.
- To identify potential neurobiological mechanisms underlying oxytocin's impact on caregiver burden.
- To provide preliminary efficacy and safety data to inform larger, definitive clinical trials.
Why It Matters
If this Phase 2 trial demonstrates positive results, it could establish intranasal oxytocin as a viable intervention for mitigating chronic stress in dementia caregivers. This would offer a significant, non-invasive therapeutic option for a population often overlooked in clinical care. The specific daily dosing regimens (12 IU or 24 IU for 21 days) being tested are crucial for developing a practical protocol. Positive fMRI findings could also provide objective biomarkers for oxytocin's efficacy, guiding personalized treatment strategies. This research is a critical step towards translating oxytocin's known prosocial and anxiolytic effects into a clinically applicable strategy for improving caregiver mental health and resilience.
oxytocin
stress
dementia
caregivers
intranasal
clinical trial